Search

Showing total 377 results

Search Constraints

Start Over You searched for: Search Limiters Full Text Remove constraint Search Limiters: Full Text Topic htlv-i Remove constraint Topic: htlv-i Language english Remove constraint Language: english
377 results

Search Results

1. Human tumor viruses: induction of three-dimensional alterations in the host genome structure.

2. Prenatal diagnosis.

3. A historical reflection on the discovery of human retroviruses.

4. Global Stability of Delayed SARS-CoV-2 and HTLV-I Coinfection Models within a Host.

5. A STUDY ON HUMAN T CELL LYMPHOTROPIC VIRUS-TYPE 1 (HTLV-1) IN THE OBSTETRIC FIELD : A RATIONAL AND PRACTICAL SCREEENING SYSTEM FOR HTLV-1 CARRIERS AND POSSIBLE FACTORS FOR VERTICAL TRANSMISSION

6. Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.

7. Stability of an HTLV-HIV coinfection model with multiple delays and CTL-mediated immunity.

8. The frequency and risk factors of human T-cell lymphotropic virus type I among blood donors in Khorasan-e Razavi, Iran, from 2002 to 2013.

9. The discovery of HTLV-1, the first pathogenic human retrovirus.

10. A new drug target identified for diseases associated with leukemia-causing virus.

11. Imbalanced IL10/TGF-β production by regulatory T-lymphocytes in patients with HTLV-1-associated myelopathy/ tropical spastic paraparesis.

12. The tyrosine kinase KDR is essential for the survival of HTLV-1-infected T cells by stabilizing the Tax oncoprotein.

13. Work-Related Human T-lymphotropic Virus 1 and 2 (HTLV-1/2) Infection: A Systematic Review.

14. Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review.

15. Ripasudil as a Potential Therapeutic Agent in Treating Secondary Glaucoma in HTLV-1-Uveitis: An In Vitro Analysis.

16. Purification Method of Extracellular Vesicles Derived from Human T-Cell Leukemia Virus Type 1-Infected Cells without Virions.

17. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia–Lymphoma.

18. Qualitative evidence synthesis of values and preferences to inform infant feeding in the context of non-HIV transmission risk.

19. Dynamical behaviors of an HTLV-I infection model with intracellular delay and immune activation delay.

20. Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.

21. Detrusor Arreflexia as an End Stage of Neurogenic Bladder in HAM/TSP?

22. Curcumin targets Akt cell survival signaling pathway in HTLV-I-infected T-cell lines.

23. Epidemiological and molecular evidence of intrafamilial transmission through sexual and vertical routes in Bahia, the state with the highest prevalence of HTLV-1 in Brazil.

24. Cognitive deficits in HTLV-1 patients.

25. Ultrasensitive photoelectrochemical biosensor for the detection of HTLV-I DNA: A cascade signal amplification strategy integrating λ-exonuclease aided target recycling with hybridization chain reaction and enzyme catalysis.

26. Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis.

27. Origin and functional role of antisense transcription in endogenous and exogenous retroviruses.

28. Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.

29. How Can We Prevent Mother-to-Child Transmission of HTLV-1?

30. Phylogeny of Shrew- and Mole-Borne Hantaviruses in Poland and Ukraine.

31. Point-of-Care System for HTLV-1 Proviral Load Quantification by Digital Mediator Displacement LAMP.

32. HTLV/HIV Dual Infection: Modeling and Analysis.

33. Potential miRNA-gene interactions determining progression of various ATLL cancer subtypes after infection by HTLV-1 oncovirus.

34. Malignancy and viral infections in Sub-Saharan Africa: A review.

35. Stability analysis of SARS-CoV-2/HTLV-I coinfection dynamics model.

36. Discretization and Analysis of HIV-1 and HTLV-I Coinfection Model with Latent Reservoirs.

37. Dynamical Properties of Discrete-Time HTLV-I and HIV-1 within-Host Coinfection Model.

38. Development and Validation of a Rapid Screening Test for HTLV-I IgG Antibodies.

39. A newly identified interaction between nucleolar NPM1/B23 and the HTLV-I basic leucine zipper factor in HTLV-1 infected cells.

40. Postural Adjustments in HTLV-1 Infected Patients during a Self-Initiated Perturbation.

41. Prevalence and Risk Factors for HTLV-1/2 Infection inRiverside and Rural Populations of the State of Pará.

42. Identification of Hub Genes Associated with Abnormal Endothelial Function in Early Coronary Atherosclerosis.

43. Dynamics of HIV-1/HTLV-I Co-Infection Model with Humoral Immunity and Cellular Infection.

44. Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection in rural Gabon.

45. Construction of a miRNA-mRNA Network Related to Exosomes in Colon Cancer.

46. Identification and characterization of a novel enhancer in the HTLV-1 proviral genome.

47. Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran.

48. NF-κB Inhibition Facilitates the Establishment of Cell Lines That Chronically Produce Human T-Lymphotropic Virus Type 1 Viral Particles.

49. Clonal Selection and Evolution of HTLV-1-Infected Cells Driven by Genetic and Epigenetic Alteration.

50. HTLV-1 activates YAP via NF-κB/p65 to promote oncogenesis.